{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:49:51Z","timestamp":1768722591986,"version":"3.49.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001962","name":"World Anti-Doping Agency","doi-asserted-by":"publisher","award":["16D20FB"],"award-info":[{"award-number":["16D20FB"]}],"id":[{"id":"10.13039\/501100001962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anabolic androgenic steroids (AAS) are prohibited as performance-enhancing drugs in sports. Among them, testosterone and its precursors are often referred to as \u201cpseudoendogenous\u201d AAS, that is, endogenous steroids that are prohibited when administered exogenously. To detect their misuse, among other methods, the World Anti-Doping Agency-accredited laboratories monitor the steroid profile (concentrations and concentration ratios of endogenous steroids, precursors and metabolites) in urine samples collected from athletes in and out of competition. Alterations in steroid profile markers are used as indicators for misuse of anabolic steroids in sports. Therefore, especially their metabolic pathways with possible interactions are crucial to elucidate. As steroid metabolism is very complex, and many enzymes are involved, certain non-prohibited drugs may influence steroid metabolite excretion. One important group of steroid-metabolizing enzymes is aldo\u2013keto reductases (AKRs). An inhibition of them by non-steroidal anti-inflammatory drugs (NSAIDs), which are neither prohibited nor monitored, but frequently used drugs in sports, was demonstrated in vitro. Thus, this work aims to investigate the influence of NSAID intake on the urinary steroid profile. Kinetic and inhibitory studies were performed using 5\u03b1-dihydrotestosterone as substrate. The results obtained from in vitro experiments show that ibuprofen inhibits AKR1C2 and thus influences steroid biotransformation. For in vivo investigations, urine samples prior, during and postadministration of ibuprofen were analyzed using routine methods to monitor the steroid profile. Changes in markers of the steroid profile of volunteers were observed. The combination of in vitro and in vivo results suggests that monitoring of ibuprofen may be useful in doping control analysis. The presented work illustrates the importance to consider co-administration of (non-prohibited) drugs during antidoping analysis. Intake of multiple substances is likely leading to interfering effects. Divergent results in antidoping analysis may therefore be observed and misinterpretation of analytical data may occur. Similar considerations may be appropriate for other fields of forensic applications.<\/jats:p>","DOI":"10.1093\/jat\/bkaa049","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:09:56Z","timestamp":1588792196000},"page":"871-879","source":"Crossref","is-referenced-by-count":8,"title":["Influence of Pain Killers on the Urinary Anabolic Steroid Profile"],"prefix":"10.1093","volume":"44","author":[{"given":"Anna","family":"Stoll","sequence":"first","affiliation":[{"name":"Institute of Pharmacy, Freie Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Iannone","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"De Gregorio","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Molaioni","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Botr\u00e8","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping FMSI, Rome, Italy"},{"name":"Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kristina Parr","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Freie Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"key":"2020121209234715900_ref1","article-title":"Athlete Biological Passport Operating Guidelines-Version 7.1","author":"World Anti-Doping Agency","year":"2019"},{"key":"2020121209234715900_ref2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/dta.1448","article-title":"Reference ranges for the urinary steroid profile in a Latin-American population","volume":"5","author":"Martinez-Brito","year":"2013","journal-title":"Drug Testing and Analysis"},{"key":"2020121209234715900_ref3","first-page":"85","volume-title":"Recent Advances in Doping Analysis","author":"Mareck-Engelke","year":"1993"},{"key":"2020121209234715900_ref4","first-page":"121","volume-title":"Recent Advances in Doping Analysis (2)","author":"Mareck-Engelke","year":"1994"},{"key":"2020121209234715900_ref5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/dta.1608","article-title":"Drug-drug interaction and doping, part 2: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of stanozolol","volume":"6","author":"Mazzarino","year":"2014","journal-title":"Drug Testing and Analysis"},{"key":"2020121209234715900_ref6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/dta.1608","article-title":"Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene","volume":"6","author":"Mazzarino","year":"2014","journal-title":"Drug Testing and Analysis"},{"key":"2020121209234715900_ref7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jms.1457","article-title":"Factors influencing the steroid profile in doping control analysis","volume":"43","author":"Mareck","year":"2008","journal-title":"Journal of Mass Spectrometry"},{"key":"2020121209234715900_ref8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00042752-200301000-00007","article-title":"Medication use in athletes selected for doping control at the Sydney Olympics (2000)","volume":"13","author":"Corrigan","year":"2003","journal-title":"Clinical Journal of Sport Medicine"},{"key":"2020121209234715900_ref9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","article-title":"An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies","volume":"75","author":"Byrns","year":"2008","journal-title":"Biochemical Pharmacology"},{"key":"2020121209234715900_ref10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0009-8981(82)90315-1","article-title":"The effect of ibuprofen on the excretion of steroid metabolites","volume":"124","author":"Ball","year":"1982","journal-title":"Clinica Chimica Acta"},{"key":"2020121209234715900_ref11","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1073\/pnas.1715035115","article-title":"Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism","volume":"115","author":"Kristensen","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"2020121209234715900_ref12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.aca.2010.10.003","article-title":"Urine stability and steroid profile: towards a screening index of urine sample degradation for anti-doping purpose","volume":"683","author":"Mazzarino","year":"2011","journal-title":"Analytica Chimica Acta"},{"key":"2020121209234715900_ref13","doi-asserted-by":"crossref","first-page":"108491","DOI":"10.1016\/j.steroids.2019.108491","article-title":"Effects of transdermal administration of testosterone gel on the urinary steroid profile in hypogonadal men: Implications in antidoping analysis","volume":"152","author":"Iannone","year":"2019","journal-title":"Steroids"},{"key":"2020121209234715900_ref14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/dta.1759","article-title":"Detection of formestane abuse by mass spectrometric techniques","volume":"6","author":"De La Torre","year":"2014","journal-title":"Drug Testing and Analysis"},{"key":"2020121209234715900_ref15","article-title":"WADA Technical Document\u2013TD2018EAAS. Endogenous anabolic androgenic steroids measurement and reporting","author":"World Anti-Doping Agency","year":"2018"},{"key":"2020121209234715900_ref16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1293\/tox.2017-0050","article-title":"Statistical analysis for toxicity studies","volume":"31","author":"Hamada","year":"2018","journal-title":"Journal of Toxicologic Pathology"},{"key":"2020121209234715900_ref17","first-page":"401","volume-title":"Recent Advances in Doping Analysis","author":"Leinonen","year":"2007"},{"key":"2020121209234715900_ref18","first-page":"63","volume-title":"Assay Guidance Manual","author":"Brooks"},{"key":"2020121209234715900_ref19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbi.2008.10.015","article-title":"AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids","volume":"178","author":"Skarydov\u00e1","year":"2009","journal-title":"Chemico-Biological Interactions"},{"key":"2020121209234715900_ref20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/bi972725u","article-title":"Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione","volume":"37","author":"Burczynski","year":"1998","journal-title":"Biochemistry"},{"key":"2020121209234715900_ref21","doi-asserted-by":"crossref","first-page":"13451","DOI":"10.1021\/bi026109w","article-title":"Kinetics of allopregnanolone formation catalyzed by human 3R-hydroxysteroid dehydrogenase type III (AKR1C2)","volume":"41","author":"Trauger","year":"2002","journal-title":"Biochemistry"},{"key":"2020121209234715900_ref22","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"2020121209234715900_ref23","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"2020121209234715900_ref24","doi-asserted-by":"crossref","first-page":"W441","DOI":"10.1093\/nar\/gkp253","article-title":"IC50 to Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding","volume":"37","author":"Cer","year":"2009","journal-title":"Nucleic Acids Research"},{"key":"2020121209234715900_ref25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chemico-Biological Interactions"},{"key":"2020121209234715900_ref26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.aca.2009.10.022","article-title":"Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and\/or instrumental detection","volume":"657","author":"Mazzarino","year":"2010","journal-title":"Analytica Chimica Acta"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaa049\/33198363\/bkaa049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/44\/8\/871\/34880785\/bkaa049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/44\/8\/871\/34880785\/bkaa049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T14:24:17Z","timestamp":1607783057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/44\/8\/871\/5835193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,5,9]]},"published-print":{"date-parts":[[2020,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaa049","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,5,9]]}}}